The service package includes a PGD that authorises the supply of Tamiflu® (Oseltamivir phosphate) capsules 20mg 45mg and 75mg to help reduce the possibility of being infected with flu and reduce the time of illness from flu by up to one day. Tamiflu® is also recommended to those with a weak immune system. The authorisation of supply requires an Influenza A/B positive nasal swab, via a reliable rapid test kit. In pharmacy rapid test kits are available to buy from PharmaDoctor.

Authorised exclusive UK supplier of BioPanda Rapid Test Kits.


Tamiflu Information

About the PGD(s)

Treatments available:
• Tamiflu® (Oseltamivir phosphate) capsules 20mg 45mg and 75mg PGD

Price: £39.00

  • The Tamiflu includes the following resources

    This service package includes: Tamiflu® (Oseltamivir phosphate) capsules 20mg 45mg and 75mg PGD and access to Biopanda rapid test kits. The service packages allows in pharmacy consultation, diagnosis and treatment/prophylaxis, for patients looking to protect themselves against influenza A and B virus or avian flu.

All our PGD service packages come with free access to our 9-5 Monday to Friday clinical support and medical information line.


Why this PGD

Tamiflu® (Oseltamivir phosphate) is an antiviral medicine that can shorten the length of illness if taken within 48 hours of initial symptoms appearing, please refer to product SPC. Tamiflu® (Oseltamivir phosphate) can also reduce the chance of infection by up to 50%. This PGD service enables healthcare professionals to conduct consultations that diagnose the absence or presence of influenza A and B viruses, via an in pharmacy rapid test kit, in both patients who wish to reduce the possibility of being infected and also patients already confirmed with infection and/or showing symptoms of infection. This service is especially effective as a provision via a patient group direction - as ready access to community pharmacies can produce effective public health measures.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to the relevant pharmaceutical company.